AKT1 and B-cell non-Hodgkin lymphoma: We here show that prolonged, everolimus-mediated, inhibition of mTORC1 in B-cell lymphomas results in disruption of negative feedbacks, thus leading to the hyperactivation of alternative proliferative pathways (i.e AKT and MAPK/ERK) (Fig. 5c).